Clinical Trials
2 trialsNCT06590558 2025-07-03
Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer
National Cancer Institute (NCI)
Phase 1 Withdrawn
NCT01714128 2021-10-25
FES-PET for Patients Treated on NCI Protocol 8762
Washington University School of Medicine
Phase NA Withdrawn